Unlike traditional chemotherapy, the EV+pembrolizumab combination is producing a "tail on the curve" in survival data. This indicates a significant minority of patients with metastatic bladder cancer are achieving durable, long-term responses—a phenomenon previously unseen and a paradigm shift for the disease.

The transformative efficacy of EV-Pembro has ushered in a new, aggressive treatment philosophy for both muscle-invasive and metastatic bladder cancer. The approach is to administer the combination upfront to gain rapid disease control, and only then make subsequent decisions about surgery, radiation, or further therapy.

The EV Pembro combination is the new first-line standard for metastatic bladder cancer, replacing platinum chemotherapy. This shift leaves clinicians without clear, trial-backed evidence for second-line treatment, as previous trials for other agents were all designed for post-platinum progression.

For elderly or frail patients with metastatic bladder cancer, treatment choice hinges on goals. Enfortumab vedotin (EV) monotherapy is preferred for a rapid response in symptomatic or bulky disease. In contrast, pembrolizumab monotherapy is better for a lower-intensity approach in patients with low-volume disease where durable benefit and quality of life are prioritized.

An expert speculates that the durable responses and plateauing four-year survival curve from the EV302 trial indicate a potential cure rate of 30% in metastatic bladder cancer, a dramatic improvement over historical outcomes of 5-10%.

While both the B15 (EV Pembro) and Niagara (Gem-Cis-Durvalumab) trials were positive, B15 demonstrated a significantly higher pathologic complete response rate (56% vs 37%) and more favorable hazard ratios for survival endpoints. This suggests EV Pembro is the "more positive" regimen and likely the preferred standard of care.

With therapies like Enfortumab Vedotin + Pembrolizumab (EVPembro) inducing a pathological complete response (PathCR) in 60% of patients, many undergo radical cystectomies only to find no residual cancer. This success rate is driving trials for bladder-sparing approaches like active surveillance.

The demonstrated superiority of the enfortumab vedotin (EV) and pembrolizumab combination over platinum chemotherapy has effectively made the Galski criteria, used for determining cisplatin eligibility, irrelevant. This marks a major paradigm shift in how frontline bladder cancer is approached, moving beyond platinum-based decisions.

In cisplatin-ineligible muscle-invasive bladder cancer, neoadjuvant enfortumab vedotin plus pembrolizumab demonstrated a 57% pathologic complete response rate in the KEYNOTE-905 trial. This is an unprecedented result, significantly higher than any previously studied regimen and signals a major shift in perioperative treatment.